Tech Company Financing Transactions

AsclepiX Therapeutics Funding Round

AsclepiX Therapeutics, based in Baltimore, secured $35 million from Perceptive Advisors, Barer & Son Capital and Rapha Capital Management.

Transaction Overview

Company Name
AsclepiX Therapeutics
Announced On
6/25/2020
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors

Perceptive Advisors (Lead Investor) (Chris Garabedian)

Barer & Son Capital (Josh Barer)

Rapha Capital Management (Kevin Slawin)

Proceeds Purpose
The proceeds from the financing will fund Phase 1/2a clinical trials of AXT107, the Company's lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (wet AMD) and macular edema secondary to retinal vein occlusion (RVO).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
301 West 29th St. 2004
Baltimore, MD 21211
USA
Phone
(410) 657-2627
Website
www.asclepix.com
Email Address
[email protected]
Overview
AsclepiX Therapeutics is focussed on transforming the treatment of retinal disease and cancer through the rapid clinical development of groundbreaking therapies which may empower patients and families around the world with the freedom to live their best lives.
Profile
AsclepiX Therapeutics LinkedIn Company Profile
Social Media
AsclepiX Therapeutics Company Twitter Account
Company News
AsclepiX Therapeutics News
Facebook
AsclepiX Therapeutics on Facebook
YouTube
AsclepiX Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kevin Slawin
  Kevin Slawin LinkedIn Profile  Kevin Slawin Twitter Account  Kevin Slawin News  Kevin Slawin on Facebook
Chief Medical Officer
Theresa Heah
  Theresa Heah LinkedIn Profile  Theresa Heah Twitter Account  Theresa Heah News  Theresa Heah on Facebook
Chief Scientific Officer
Aleksander Popel
  Aleksander Popel LinkedIn Profile  Aleksander Popel Twitter Account  Aleksander Popel News  Aleksander Popel on Facebook
Chief Technical Officer
Jordan Green
  Jordan Green LinkedIn Profile  Jordan Green Twitter Account  Jordan Green News  Jordan Green on Facebook
VP - R & D
Niranjan Pandey
  Niranjan Pandey LinkedIn Profile  Niranjan Pandey Twitter Account  Niranjan Pandey News  Niranjan Pandey on Facebook
VP - R & D
Huan Sheng
  Huan Sheng LinkedIn Profile  Huan Sheng Twitter Account  Huan Sheng News  Huan Sheng on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/25/2020: Steady venture capital transaction
Next: 6/25/2020: OJO Labs venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.